David Coeffic, MD

Articles by David Coeffic, MD

European Experience With Irinotecan Plus Fluorouracil/Folinic Acid or Mitomycin

ByDavid Khayat, MD, PhD,Marian Gil-delgado, MD, PhD,Eric-charles Antoine, MD,David Coeffic, MD,A. Benhammouda, MD,J. P. Grapin, MD,Gerard Bastian, PhD

August 1st 1998

Tremendous progress has been made in the medical treatment of advanced colorectal cancer during the past 2 to 3 years, due to the availability of several new drugs. Of these new agents, irinotecan (CPT-11 [Camptosar]) seems

Latest Updated Articles

European Experience With Irinotecan Plus Fluorouracil/Folinic Acid or Mitomycin
Published: August 1st 1998 | Updated:

David Coeffic, MD

Articles by David Coeffic, MD

European Experience With Irinotecan Plus Fluorouracil/Folinic Acid or Mitomycin

Latest Updated Articles

Trending on CancerNetwork

FDA OKs Subcutaneous Amivantamab in EGFR+ NSCLC

FDA Grants Regular Approval to Rucaparib in Metastatic CRPC

Imlunestrant Combo Will Not Be Pursued for FDA Approval in Breast Cancer

Gathering Data to Ascertain Biomarker Specificity in HER2– Breast Cancer

Elacestrant Regimens Yield Meaningful PFS in ER+/HER2– Breast Cancer